Testing a New mRNA Cancer Treatment for Advanced Solid Tumors
Part of Cancer clinical trials.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer (spread or come back) that did not respond to at least two lines of prior treatment, with no other standard options available
- Your overall health is good enough to tolerate treatment (ECOG score 0–1, meaning you can do most daily activities)
- You are expected to live at least 3 months
- At least 4 weeks have passed since your last chemotherapy, radiotherapy, or surgery
- Your blood counts, liver, and kidney function are adequate; your heart pumps well (ejection fraction ≥50%)
- You have no uncontrolled heart disease, active infections (including HIV, hepatitis, or tuberculosis), or active autoimmune diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, IL-22BP/LNP, for people with advanced solid tumors (like soft tissue sarcoma, head and neck cancer, melanoma) that have worsened after standard treatments. The main goals are to see if the drug is safe and tolerable, and to learn if it might help shrink or slow the cancer.
This trial tests a new drug that may help people with advanced solid tumors that have not responded to other treatments. The drug is given as an injection and aims to stop cancer growth.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
This trial tests a new experimental drug (called NCP-IL-22BP mRNA) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe, tolerable, and maybe effective against the cancer.
This trial tests a new type of immunotherapy that is injected directly into a tumor. The treatment uses mRNA (genetic material) wrapped in a fat particle to stimulate your immune system to attack the cancer. It's for people with advanced solid tumors that haven't responded to standard treatments.
This trial tests a personalized mRNA vaccine (RH125) designed to train your immune system to attack your cancer. It is for people with advanced solid tumors that have not responded to standard treatments, and it aims to see if the vaccine is safe and helpful.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.